Theolytics

Theolytics, a biotechnology company based in the United Kingdom, is dedicated to transforming patients’ lives through world-leading science and a great team. Founded in 2017, Theolytics is at the forefront of oncolytic viral therapy, harnessing viruses to combat cancer. The company's phenotypic screening Platform represents a significant advancement in the field, enabling the discovery and development of targeted candidates suitable for intravenous delivery and optimized for specific patient populations. In addition to advancing an internal pipeline of programs spanning both solid and liquid tumors, Theolytics has secured a significant £19.00M Venture Round investment on 17 April 2024. Notable investors involved in this round include Epidarex Capital, MERL Ventures Fund, Oxford Science Enterprises, Taiho Ventures, Sound Bioventures, and the University of Oxford. The company is also establishing strategic partnerships to further expand and accelerate pipeline development in the biotechnology industry. In summary, Theolytics stands out for its innovative approach to leveraging viruses for cancer treatment, evidenced by its recent substantial investment and prominent investor involvement. As it continues to make advancements in the field and build strategic collaborations, Theolytics holds significant potential in the biotechnology sector.